276 related articles for article (PubMed ID: 20187016)
1. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Vaisman A; Orlov S; Yip J; Hu C; Lim T; Dowar M; Freeman JL; Walfish PG
Head Neck; 2010 Jun; 32(6):689-98. PubMed ID: 20187016
[TBL] [Abstract][Full Text] [Related]
2. Commentary: Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Terris DJ
Head Neck; 2010 Jun; 32(6):698-9. PubMed ID: 20187017
[No Abstract] [Full Text] [Related]
3. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
5. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
[TBL] [Abstract][Full Text] [Related]
6. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
7. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
9. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
[TBL] [Abstract][Full Text] [Related]
10. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
12. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
[TBL] [Abstract][Full Text] [Related]
14. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
Saengsuda Y
J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
[TBL] [Abstract][Full Text] [Related]
16. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
18. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors.
Leboeuf R; Emerick LE; Martorella AJ; Tuttle RM
Thyroid; 2007 Jun; 17(6):543-7. PubMed ID: 17614775
[TBL] [Abstract][Full Text] [Related]
19. [Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].
Díez JJ; Grande E; Iglesias P
Med Clin (Barc); 2015 Jan; 144(1):35-41. PubMed ID: 24613061
[TBL] [Abstract][Full Text] [Related]
20. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]